{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000033","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.087235+00:00","generated_at":"2026-05-30T08:19:03.919081+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NovoCure Q3 revenue +22% to $155M; FDA OKs Optune Lua; CEO/CFO transitions set","bullets":["Q3 net revenues $155.1M (+22% YoY); net loss $30.6M ($0.28 loss per share); adjusted EBITDA $1.7M.","FDA approved Optune Lua for metastatic NSCLC; Breakthrough Device designation for brain metastases from NSCLC.","CEO Asaf Danziger retiring Jan 1, 2025; CFO Ashley Cordova to become CEO on that date.","Christoph Brackmann appointed CFO (from Moderna), effective Jan 1, 2025; compensation disclosed.","Active patients on therapy 4,113; prescriptions up 8% to 1,586; cash and equivalents $959.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000033","json":"https://secwatch.observer/filing/0001645113-24-000033.json","markdown":"https://secwatch.observer/filing/0001645113-24-000033.md","text":"https://secwatch.observer/filing/0001645113-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/0001645113-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/nvcr-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:19:03.919081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98f5b20067","claim":"Christoph Brackmann was appointed as Chief Financial Officer at NovoCure Ltd.","evidence_excerpt":"On October 30, 2024, the Company announced the appointment of Christoph Brackmann, age 51, as the Chief Financial Officer of the Novocure Group, effective January 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/0001645113-24-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}